Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.b

Valvular heart disease and/or dysfunction

Publications

Frachon I, Etienne Y, Jobic Y, Le Gal G, Humbert M, Leroyer C

Benfluorex and unexplained valvular heart disease: a case-control study.

PloS one. 2010;5(4):e10128

Fleming RM, Boyd LB

The longitudinal effects of fenfluramine-phentermine use.

Angiology. 2007;58(3):353-9

McDonald PC, Wilson JE, Gao M, McNeill S, Spinelli JJ, Williams OD, Harji S, Kenyon J, McManus BM

Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion?

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 2002;11(5):251-62

Goldstein SE, Levy Y, Shoenfeld Y

[Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants].

Harefuah. 1998;135(11):489-92, 568

Steffee CH, Singh HK, Chitwood WR

Histologic changes in three explanted native cardiac valves following use of fenfluramines.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 1999;8(5):245-53

Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, Douglas PS

Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.

Annals of internal medicine. 1998;129(11 Pt 1):870-4

Devereux RB

Appetite suppressants and valvular heart disease.

The New England journal of medicine. 1998;339(11):765-6

Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.

The New England journal of medicine. 1998;339(11):719-24

Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.

The New England journal of medicine. 1998;339(11):713-8